Sarah C. Nyirjesy

Sarah C. Nyirjesy

Auto-generated profile, based on publicly available information

Sarah C. Nyirjesy

Department of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Massachusetts Eye and Ear/Mass General Brigham, 243 Charles St, Boston, MA 02114, United States

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2023 in Oral Oncology
Verified
Journal Article
Closed access
MHMargaret A. Heller
Margaret A. Heller
SNSarah C. Nyirjesy
Sarah C. Nyirjesy
RBRobert Balsiger
Robert Balsiger
NTNicholas Talbot
Nicholas Talbot
KVKyle K. VanKoevering
Kyle K. VanKoevering
NSNolan Seim
Nolan Seim

23 January 2023 in The Laryngoscope
Verified
Journal Article
Open access
NTNicholas Talbot
Nicholas Talbot
MHMargaret Heller
Margaret Heller
SNSarah Nyirjesy
Sarah Nyirjesy
BKBrandon Kim
Brandon Kim
BDBrad DeSilva
Brad DeSilva
LMLaura Matrka
Laura Matrka
Objective: Neurogenic cough related to hypersensitivity of the internal branch of the superior laryngeal nerve (SLN) is often treated with neuromodulating medications, which can cause considerable side effects. An alternative therapy is steroid and local anesthetic injection of the SLN (“SLN block”), initially proposed to benefit those with lateralizing symptoms (tenderness over the thyrohyoid membrane or unilateral cough source). Our objectives are to determine if SLN block produces subjective symptomatic improvements and if repeat injections further improve symptoms, and evaluate clinical factors potentially predictive of response.Methods: Retrospective chart review of 54 patients receiving SLN blocks at a tertiary medical academic center from January 2010 to June 2020. Medical history and anticipated predictors of positive response, including stigmata of laryngeal hypersensitivity, were recorded. Outcomes included symptomatic response, number of injections required, and side effects. Response was defined subjectively by asking patients whether the injection was beneficial and objectively by using CSI scores.Results: Fifty‐four patients met the inclusion criteria. Thirty‐eight patients (70.4%) endorsed improvement. No variables were identified as positive predictors of response. Thirty‐two of the 38 (84.2%) endorsed improvement after one injection. Six of 15 (40%) patients who failed the first injection had positive response to the second. No significant side effects were reported.Conclusion: No localizing symptoms, specific cough features, or aspects of the medical history helped predict response, suggesting that a broader range of patients may be offered the intervention. The majority of patients reported symptomatic improvement and repeat injections may benefit patients with initial nonresponse.Level of Evidence: 4 Laryngoscope, 133:2647–2653, 2023

1 October 2020 in Otology & Neurotology
Verified
Journal Article
Closed access
SNSarah Nyirjesy
Sarah Nyirjesy
CRCole Rodman
Cole Rodman
TTTerrin N. Tamati
Terrin N. Tamati
AMAaron C. Moberly
Aaron C. Moberly
Objective: To assess the benefits of bimodal listening (i.e., addition of contralateral hearing aid) for cochlear implant (CI) users on real-world tasks involving high-talker variability speech materials, environmental sounds, and self-reported quality of life (quality of hearing) in listeners’ own best-aided conditions. Study Design: Cross-sectional study between groups. Setting: Outpatient hearing clinic. Patients: Fifty experienced adult CI users divided into groups based on normal daily listening conditions (i.e., best-aided conditions): unilateral CI (CI), unilateral CI with contralateral HA (bimodal listening; CIHA), or bilateral CI (CICI). Intervention: Task-specific measures of speech recognition with low (Harvard Standard Sentences) and high (Perceptually Robust English Sentence Test Open-set corpus) talker variability, environmental sound recognition (Familiar Environmental Sounds Test-Identification), and hearing-related quality of life (Nijmegen Cochlear Implant Questionnaire). Main Outcome Measures: Test group differences among CI, CIHA, and CICI conditions. Results: No group effect was observed for speech recognition with low or high-talker variability, or hearing-related quality of life. Bimodal listeners demonstrated a benefit in environmental sound recognition compared with unilateral CI listeners, with a trend of greater benefit than the bilateral CI group. There was also a visual trend for benefit on high-talker variability speech recognition. Conclusions: Findings provide evidence that bimodal listeners demonstrate stronger environmental sound recognition compared with unilateral CI listeners, and support the idea that there are additional advantages to bimodal listening after implantation other than speech recognition measures, which are at risk of being lost if considering bilateral implantation.

10 April 2023 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Open access
SNSarah C. Nyirjesy
Sarah C. Nyirjesy
JYJane Yu
Jane Yu
SDSayali Dharmadhikari
Sayali Dharmadhikari
LLLumei Liu
Lumei Liu
MBMaxwell Bergman
Maxwell Bergman
TCTendy Chiang
Tendy Chiang
Objective: Long‐segment tracheal defects require tissue replacement for successful reconstruction. Rapid revascularization is imperative to maintain graft function. We previously showed that partially decellularized tracheal grafts (PDTG) and composite tracheal grafts (CTG; PDTG supported by a 3‐dimensionally printed external splint) regenerate respiratory epithelium and may support the regeneration of endothelial cells (CD31+). However, the capability of graft endothelial cells to organize or contribute to tracheal revascularization remains unclear. In this study, we quantified endothelial cells (CD31+) and neovessel formation in PDTG and CTG. We hypothesize that PDTG and CTG support tracheal neovascularization to a similar extent as surgical (syngeneic tracheal graft [STG]) and native trachea (NT) controls.Study Design: The animal study, a randomized control trial.Setting: Center for Regenerative Medicine, Nationwide Children's Hospital.Methods: PDTG was created via an established decellularization protocol. Segmental tracheal reconstruction was performed with STG, PDTG, or CTG using a mouse microsurgical model. NT was used as a nonsurgical control. At 1 month, mice were euthanized, grafts harvested, sectioned, and stained with CD31 and hematoxylin and eosin. Neovessel formation was quantified by the number of formed blood vessels in the lamina propria and vessel size (vessel/graft area, mm2).Results: Decellularization eliminated all endothelial cells and there were no perfused vessels at implantation. At 1 month, PDTG and CTG supported neovessel formation with tubular vessels lined with endothelial cells. There was no difference in the number or size of vessels compared to controls.Conclusion: PDTG and CTG support tracheal endothelial cell regeneration and neovessel formation. Future directions to assess the function, kinetics, and distribution of graft neovessels are needed.

28 March 2023 in Head & Neck
Verified
Journal Article
Open access
SNSarah C. Nyirjesy
Sarah C. Nyirjesy
RFRachel Fenberg
Rachel Fenberg
MHMargaret A. Heller
Margaret A. Heller
RJRyan T. Judd
Ryan T. Judd
MLMichael M. Li
Michael M. Li
KVKyle VanKoevering
Kyle VanKoevering
Background: Sinonasal malignancy (SNM) is a heterogeneous group of diseases for which induction chemotherapy (IC) may reduce tumor burden. The purpose of this study was to characterize the response to IC in SNM as a prognostic factor through its effect on survival.Methods: Retrospective cohort of patients undergoing IC for SNM between 2010 and 2019 at our quaternary referral center.Results: Forty‐two patients with advanced SNM were included in the analysis. Patients with a favorable response to IC had higher survival rates than those who had an unfavorable response (5‐year OS: 66.8% vs. 9.7%; p < 0.001; PFS: 56.8% vs. 0%; p < 0.001).Conclusions: Response to IC in our patient cohort was a prognostic indicator of overall response to treatment. Further elucidation of predictors of response is needed for appropriate patient selection.

1 June 2023 in Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
MAMaariyah Ahmed
Maariyah Ahmed
LMLuigi E. Melaragno
Luigi E. Melaragno
SNSarah C. Nyirjesy
Sarah C. Nyirjesy
NWNatalia von Windheim
Natalia von Windheim
RFRachel Fenberg
Rachel Fenberg
KVKyle VanKoevering
Kyle VanKoevering